Editas Medicine
Tracked across 2 events · 13 articles · First seen Aug 04, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Editas Medicine announced the board appointment, which is part of its ongoing efforts to strengthen leadership as it advances EDIT-401. The company's stock may see a slight positive sentiment due to the addition of a renowned expert.
Aug 04, 2026 · 6 articles
Business
Editas Medicine, a U.S. gene editing company, announced on September 8, 2026, the appointment of Dan Ory, M.D., as Chief Medical Officer, effective immediately. Dr. Ory, a biotechnology executive with over 25 years of experience…
Impact: Editas Medicine appointed Dan Ory as Chief Medical Officer to lead clinical development as it advances EDIT-401 toward the clinic. This executive addition is expected to support its pipeline progression.
Sep 08, 2026 · 7 articles
70
Editas Medicine appointed Dan OryEditas Medicine Appoints...
ERGEN INTELLIGENCE
Track Editas Medicine live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard